ホーム>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>PNU288034

PNU288034

カタログ番号GC32259

PNU288034 は強力なオキサゾリジノン系抗生物質です。

Products are for research use only. Not for human use. We do not sell to patients.

PNU288034 化学構造

Cas No.: 383199-88-0

サイズ 価格 在庫数 個数
1mg
$1,324.00
在庫あり
5mg
$2,979.00
在庫あり
10mg
$5,066.00
在庫あり
20mg
$8,935.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

PNU288034 is a potent oxazolidinone antibiotic.

In vitro studies conducted to characterize the transporters involved demonstrates PNU-288034 uptake by human organic anion transporter 3 (OAT3; Km = 44 +/- 5 μM) and human multidrug and toxin extrusion protein 1 (hMATE1; Km = 340 +/- 55 μM)[1].

PNU-288034 is metabolically stable in liver microsomes across species, and unchanged drug is cleared in the urine by an apparent active renal secretion process in rat and monkey. Coadministration of PNU-288034 and the OAT3 inhibitor probenecid significantly increases PNU-288034 plasma area under the curve (170%) and reduces both plasma and renal clearance in monkey. Coadministration of PNU-288034 and cimetidine also reduces plasma clearance in rat to a rate comparable with probenecid coadministration[1].

[1]. Lai Y, et al. Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1). J Pharmacol Exp Ther. 2010 Sep 1;334(3):936-44.

レビュー

Review for PNU288034

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PNU288034

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.